Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

N0590200

Nicotine ditartrate

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

(−)-Nicotine hydrogen tartrate salt, (−)-1-Methyl-2-(3-pyridyl)pyrrolidine (+)-bitartrate salt

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C10H14N2 · 2C4H6O6
Número CAS:
65-31-6
Peso molecular:
462.41
Número CE:
200-607-2
Código UNSPSC:
41116107
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

nicotine

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

cadeia de caracteres SMILES

CN1CCC[C@H]1C2=CC=CN=C2.C

InChI

1S/C10H14N2.CH4/c1-12-7-3-5-10(12)9-4-2-6-11-8-9;/h2,4,6,8,10H,3,5,7H2,1H3;1H4/t10-;/m0./s1

chave InChI

RYYKFQGHMYGLEL-PPHPATTJSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Nicotine ditartrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Ações bioquímicas/fisiológicas

Prototype nicotinic acetylcholine receptor agonist; naturally occurring isomer.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

Y0001023

Nicotine for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001425

Nicotine ditartrate dihydrate, European Pharmacopoeia (EP) Reference Standard

1463304

Nicotine bitartrate dihydrate, United States Pharmacopeia (USP) Reference Standard

1327408

6-Hydroxynicotinic acid, United States Pharmacopeia (USP) Reference Standard

1463371

Nicotine Related Compound F, United States Pharmacopeia (USP) Reference Standard

1463337

Nicotine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1463382

Nicotine Related Compound G, United States Pharmacopeia (USP) Reference Standard

1463326

Nicotine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1463348

Nicotine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1463360

Nicotine Related Compound E, United States Pharmacopeia (USP) Reference Standard

1463359

Nicotine Related Compound D, United States Pharmacopeia (USP) Reference Standard

BP822

Nicotine impurity standard, British Pharmacopoeia (BP) Reference Standard

BP821

(−)-Nicotine hydrogen tartrate salt dihydrate, British Pharmacopoeia (BP) Reference Standard

PHR2533

Nicotine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2470

6-Hydroxynicotinic acid, Pharmaceutical Secondary Standard; Certified Reference Material

PHR3060

Nicotine Related Compound A/EP Impurity A, pharmaceutical secondary standard, certified reference material

PHR3061

Nicotine Related Compound B, pharmaceutical secondary standard, certified reference material

PHR3063

Nicotine Related Compound F, pharmaceutical secondary standard, certified reference material

PHR3064

Nicotine Related Compound G, pharmaceutical secondary standard, certified reference material

Palavra indicadora

Danger

Classificações de perigo

Acute Tox. 2 Inhalation - Acute Tox. 3 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2

Código de classe de armazenamento

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

289.8 °F

Ponto de fulgor (°C)

143.2 °C

Choose from one of the most recent versions:

Certificados de análise (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 2

1 of 2

(−)-Nicotine solution 1.0 mg/mL, analytical standard, for drug analysis

Supelco

N5511

(−)-Nicotine solution

(-)-Nicotine for synthesis

Sigma-Aldrich

8.20877

(-)-Nicotine

José-Rubén García-Montes et al.
Molecular neurobiology, 56(6), 4037-4050 (2018-09-28)
L-DOPA is the main pharmacological therapy for Parkinson's disease. However, long-term exposure to L-DOPA induces involuntary movements termed dyskinesia. Clinical trials show that dyskinesia is attenuated by metabotropic glutamate receptor type 5 (mGluR5) antagonists. Further, the onset of dyskinesia is
Gabriel Quiroz et al.
Frontiers in pharmacology, 10, 1429-1429 (2019-12-19)
Brain nicotinic acetylcholine receptors (nAChRs), a heterogeneous family of pentameric acetylcholine-gated cation channels, have been suggested as molecular targets for the treatment of alcohol abuse and dependence. Here, we examined the effect of the competitive nAChR antagonist UFR2709 on the
Xueliang Shang et al.
Molecular neurobiology, 54(6), 4644-4658 (2016-07-14)
The aim of this study was to examine if nicotine was able to improve cognition deficits in a mouse model of chronic mild stress. Twenty-four male C57BL/6 mice were divided into three groups: control, stress, and stress with nicotine treatment.
Manal A Bakathir et al.
Saudi medical journal, 37(10), 1127-1135 (2016-09-22)
To investigate the effects of nicotine on orthodontic tooth movement and accompanying histological and immunohistochemical changes in rats. An experimental study conducted at King Abdulaziz University, Jeddah, Saudi Arabia between 2013 and 2014. Thirty-two rats randomly divided into 4 groups.
Monica M Arnold et al.
Neuropharmacology, 85, 293-304 (2014-06-08)
Tobacco use is the leading cause of preventable death. Although the health risks are well known, cessation rates remain low. Whereas behavioral and neuroanatomical studies on tobacco addiction conventionally use nicotine, there is evidence that other constituents, such as monoamine
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica